This site is intended for healthcare professionals
FDA Hero Banner - Multi-coloured pills and tablets
FDA Drug information

Methylprednisolone

Read time: 1 mins
Marketing start date: 02 May 2024
...
 

Summary of product characteristics


Effective Time

20221031

Version

5

Spl Product Data Elements

methylprednisolone methylprednisolone METHYLPREDNISOLONE METHYLPREDNISOLONE CELLULOSE, MICROCRYSTALLINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN WHITE TO OFF-WHITE OVAL 916 methylprednisolone methylprednisolone METHYLPREDNISOLONE METHYLPREDNISOLONE CELLULOSE, MICROCRYSTALLINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN WHITE TO OFF-WHITE OVAL 917 methylprednisolone methylprednisolone METHYLPREDNISOLONE METHYLPREDNISOLONE CELLULOSE, MICROCRYSTALLINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN WHITE TO OFF-WHITE OVAL 918 methylprednisolone methylprednisolone METHYLPREDNISOLONE METHYLPREDNISOLONE CELLULOSE, MICROCRYSTALLINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN WHITE TO OFF-WHITE OVAL 919

Application Number

ANDA206751

Brand Name

Methylprednisolone

Generic Name

methylprednisolone

Product Ndc

70771-1349

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1348-1 in bottle of 100 tablets Methylprednisolone tablets, USP R x only 100 tablets NDC 70771-1349-8 in bottle of 25 tablets Methylprednisolone tablets, USP R x only 25 tablets NDC 70771-1350-7 in bottle of 50 tablets Methylprednisolone tablets, USP R x only 50 tablets NDC 70771-1351-8 in bottle of 25 tablets Methylprednisolone tablets, USP R x only 25 tablets methylprednisolone tablets methylprednisolone tablets methylprednisolone tablets methylprednisolone tablets

Relevant Learning Zones

Psoriasis Academy
Plaque psoriasis

When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.
Pediatric Atopic Dermatitis
Paediatric Dermatitis

Are we doing enough for our pediatric patients? Discover the pathophysiology, disease burden, current management, and unmet needs of moderate-to-severe atopic dermatitis patients.
Supportive care in oncology Learning Zone
Doctor holding patient

Supportive care in oncology from a multidisciplinary team involves caring for patients with cancer, treatment adherence and adverse effect management.

Drug section

Plaque psoriasis
Plaque psoriasis
Learning Zone Homepage

Psoriasis Academy

When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.

Read more
910 mins
Learning Zone Homepage

Supportive care in oncology Learning Zone

Supportive care in oncology from a multidisciplinary team involves caring for patients with cancer, treatment adherence and adverse effect management.

Read more
150 mins
Learning Zone Homepage

Pediatric Atopic Dermatitis

Are we doing enough for our pediatric patients? Discover the pathophysiology, disease burden, current management, and unmet needs of moderate-to-severe atopic dermatitis patients.

Learn more
30 mins
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.